News Releases

Date Title and Summary Additional Formats
Toggle Summary Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. , May 31, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on May 31, 2019 , that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s
View HTML
Toggle Summary Sarepta Therapeutics Statement on ICER Draft Evidence Report for Treatments for Duchenne Muscular Dystrophy
CAMBRIDGE, Mass., May 23, 2019 -- Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, released the following statement on the report from the Institute for Clinical and Economic Review (“ICER”) on treatments for Duchenne muscular dystrophy: Sarepta is committed
View HTML
Toggle Summary Sarepta Therapeutics Announces First Quarter 2019 Financial Results and Recent Corporate Developments
CAMBRIDGE, Mass. , May 08, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the three months ended March 31, 2019 . “Having built out our multi-platform portfolio of genetic medicine
View HTML
Toggle Summary Sarepta Announces Agreement with Nationwide Children’s Hospital for Rights to its Gene Therapy Program to Treat Limb-Girdle Muscular Dystrophy Type 2A, the Most Common Form of Limb-Girdle Muscular Dystrophy
--Expands pipeline with 6 th investigational gene therapy for Limb-girdle muscular dystrophy-- --Furthers the Company’s commitment to finding treatments for neuromuscular conditions-- CAMBRIDGE, Mass. , May 08, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc.
View HTML
Toggle Summary Sarepta Therapeutics to Announce First Quarter 2019 Financial Results and Recent Corporate Developments on May 8, 2019
CAMBRIDGE, Mass. , May 01, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2019 financial results after the Nasdaq Global Market closes on Wednesday, May 8, 2019 . Subsequently, at 4:30 p.m.
View HTML
Toggle Summary Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. , April 30, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on April 30, 2019 , that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s
View HTML
Toggle Summary Sarepta Therapeutics’ Gene Therapy Limb-Girdle Muscular Dystrophy Type 2E Clinical Data has been Accepted for a Late-breaking Oral Presentation at the 2019 MDA Clinical and Scientific Conference
--Six additional poster presentations highlighting data from Sarepta’s RNA and gene therapy programs also accepted-- CAMBRIDGE, Mass. , April 08, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today stated that its
View HTML
Toggle Summary Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. , March 29, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 29, 2019 , that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s
View HTML
Toggle Summary Sarepta Therapeutics Announces Positive Expression Results from the Casimersen (SRP-4045) Arm of the ESSENCE Study
-- Interim analysis found statistically significant increase in dystrophin production as measured by western blot in casimersen-treated participants compared to baseline and placebo --      -- Based on positive results, Company intends to schedule a pre-NDA meeting with FDA and plans to submit an
View HTML
Toggle Summary Sarepta Therapeutics to Provide Update on Duchenne Muscular Dystrophy Gene Therapy Program
CAMBRIDGE, Mass. , March 25, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced that it will host a webcast and conference call at 8:00 a.m. Eastern Time (ET) on Monday, March 25, 2019 .
View HTML

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.

There are no items to display.